Navigation Links
Making Science Personal: Lilly Oncology to Unveil 76 Studies at,ASCO 2007

37 Thoracic Cancer Studies; 11 Breast Cancer Studies; 9 Targeted Agent Studies

INDIANAPOLIS, May 23, 2007 /PRNewswire-FirstCall/ -- Lilly Oncology will unveil 76 studies at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1-5, 2007. The company will present important data on GEMZAR(R) (gemcitabine HCl for injection), ALIMTA(R) (pemetrexed for injection), and enzastaurin, an investigational, oral, targeted therapy. There will also be numerous studies that continue to use GEMZAR and ALIMTA as chemotherapeutic foundations in innovative combinations with new targeted therapies.

"This is an exciting time in cancer research as we are moving away from 'one-size fits all' treatment," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "Lilly's commitment to finding the right drug, at the right dose, for the right patient at the right time will be demonstrated at ASCO this year."

    Key Lilly Abstracts for ASCO 2007:

    -- ALIMTA(R) (pemetrexed for injection)

        -- Phase III Study of ALIMTA in First-line NSCLC

            -- Abstract # 7517: June 2, 2007; 3:00 p.m.

            -- Pemetrexed + carboplatin vs. gemcitabine + carboplatin in the

                treatment of stage IIIB/IV NSCLC


        -- Large Meta-analysis of Diverse Patients with NSCLC

            -- Publication: 2007 ASCO Meeting Program

            -- Effect of race on the safety and efficacy of pemetrexed therapy

               in locally advanced and metastatic non-small cell lung cancer

               (NSCLC)


        -- Phase II Evaluation of ALIMTA Using Accelerated Vitamin

           Supplementation in Small Cell Lung Cancer

            -- Abstract # 7726: June 3, 2007: 8:00 a.m.

            -- The impact of shortened vitamin supplementation lead-in time

               before pemetrexed in patients with relapsed small cell lung

               cancer (SCLC)



        -- Early-phase Trial of ALIMTA +/- Steroids in Head & Neck Cancer

            -- Abstract # 6055: June 4, 2007: 1:00 p.m.

            -- A phase I dose escalation study of pemetrexed in patients with

               advanced head and neck squamous cell cancer


    -- GEMZAR(R) (gemcitabine HCl for injection)

        -- Phase III Study of GEMZAR Combination in Neoadjuvant (Pre-Surgical)

           Breast Cancer

            -- Abstract # 595: June 2, 2007; 2:00 p.m.

            -- Neoadjuvant chemotherapy with a dose-dense sequential

               combination of epirubicin and cyclophosphamide followed by

               paclitaxel and gemcitabine +/- trastuzumab in stage II and III

               breast cancer


    -- Enzastaurin

        -- Phase II Data of Targeted, Oral Agent enzastaurin in Second- &

           Third-line NSCLC

            -- Abstract # 7543: June 2, 2007; 8:00 a.m.

            -- A phase II study of enzastaurin as second- or third-line

               treatment of non-small cell lung cancer (NSCLC)

For more information on Lilly Oncology agents, including full prescribing information, please see the attached fact sheet, or, if you are receiving this electronically, you can view full prescribing information on www.lillyoncology.com.

CONTACT: Gregory L. Clarke, +1-317-276-5222, or Mobile, +1-317-554-7119,or Christine Van Marter, +1-317-651-1473, or Mobile, +1-317-554-7923, bothof Eli Lilly and Company

Ticker Symbol: (:LLY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
7. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
8. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
9. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... January 19, 2017 ... Oncology & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to ... from touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the German ... Germany , has purchased a MRIdian ... Clinic Heidelberg as part of its initiative for MRI-based ... be headed by Medical Director and Professor Jürgen Debus, ... German Cancer Research Center (DKFZ), the Heidelberg Heavy Ion ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based company ... attended the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding ... range of supplements that keep the body functioning at its peak performance by ...
(Date:1/20/2017)... New York, NY (PRWEB) , ... January 20, ... ... drinks – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have ... the body with optimal conditions to perform during your workout. , After a ...
(Date:1/20/2017)... ... ... You”: a fine examination of how God handles sin, including how to let go ... Miller, who, for over ten long years has been waiting to release this powerful insight ... he has been serving the Lord for over twenty years, and he has been preaching ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Knowledge is God’s Lighthouse”: a ... “Knowledge is God’s Lighthouse” is the creation of published author, Gene Gaapf, a retired ... collections. , “I have been writing since high school and have many different ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Learning Management System: an On-demand E-learning system for Clinical and Regulatory education ... that is based on Aerolib`s successful education methodology of Disease Specific Documentation ...
Breaking Medicine News(10 mins):